Hepatitis B Surface Antigen and Core Total Positive
A positive HBsAg with positive total anti-HBc indicates current hepatitis B virus infection—either acute or chronic—and the person is infectious. 1, 2
What This Serological Pattern Means
This combination of markers confirms active HBV infection. The presence of HBsAg indicates the virus is present and replicating, while total anti-HBc (which includes both IgM and IgG antibodies) confirms genuine HBV exposure rather than a false-positive HBsAg result 1, 3. This pattern is distinct from:
- Vaccination response: Would show only anti-HBs positive (no anti-HBc) 4
- Resolved infection: Would show anti-HBc and anti-HBs positive, but HBsAg negative 4, 3
- False-positive HBsAg: Would typically be anti-HBc negative 5
Distinguishing Acute vs. Chronic Infection
The critical next step is determining whether this represents acute or chronic infection:
Test for IgM anti-HBc:
- IgM anti-HBc positive = Acute infection or recent infection 1, 2
- IgM anti-HBc negative = Likely chronic infection (if HBsAg persists >6 months) 1, 2
If HBsAg remains positive for longer than 6 months, the infection is definitively chronic 4. Repeat HBsAg testing at 6 months is essential to confirm chronicity 4.
Recommended Next Steps
Immediate Evaluation (Initial Workup):
Confirm infection status:
Assess viral replication and disease activity 4:
- HBeAg/anti-HBe status
- Quantitative HBV DNA level
- ALT/AST, bilirubin, albumin, prothrombin time
- Complete blood count (assess for thrombocytopenia suggesting cirrhosis)
Screen for coinfections 4:
- Anti-HCV (hepatitis C)
- Anti-HDV (hepatitis D) if high-risk: people who inject drugs, men who have sex with men, immigrants from endemic areas 6
- Anti-HIV if high-risk group
Assess liver fibrosis stage 4, 7:
- Non-invasive: FIB-4 score or transient elastography (preferred)
- Liver biopsy optional unless results will change management
Screen for hepatocellular carcinoma 4:
- Abdominal ultrasound
- Serum alpha-fetoprotein
Treatment Considerations:
Antiviral therapy is indicated if 4, 7, 8:
- Cirrhosis is present (regardless of HBV DNA or ALT levels)
- HBeAg-positive chronic hepatitis B: HBV DNA ≥20,000 IU/mL AND ALT ≥2× upper limit of normal
- HBeAg-negative chronic hepatitis B: HBV DNA ≥2,000 IU/mL AND elevated ALT
- Moderate-to-severe necroinflammation on biopsy (≥A2 activity)
Special Populations Requiring Prophylaxis:
Even if not meeting treatment criteria for chronic hepatitis B, antiviral prophylaxis is mandatory before 9, 10:
- Immunosuppressive therapy (especially B-cell depleting agents like rituximab, high-dose corticosteroids)
- Chemotherapy
- Solid organ or stem cell transplantation
Monitoring Strategy:
For those not meeting treatment criteria 4:
- Monitor ALT, HBV DNA, and HBeAg/anti-HBe every 3-6 months
- Annual HCC surveillance (ultrasound ± AFP) for high-risk groups: men >40 years, women >50 years, family history of HCC/cirrhosis, any cirrhosis 7
Critical Pitfalls to Avoid:
Do not assume vaccination failure: Anti-HBc positivity distinguishes true infection from vaccine response 4
Do not delay coinfection screening: HDV coinfection dramatically increases HCC risk and requires different management 6, 7
Do not start immunosuppression without antiviral prophylaxis: HBV reactivation can be fatal 9, 10
Do not rely on single ALT measurement: ALT can fluctuate; serial monitoring over 3-6 months is essential 4
Confirm HBsAg positivity is not transient: Transient HBsAg positivity can occur up to 18 days post-vaccination 3